VNRX Logo

VolitionRx Limited (VNRX) 

AMEX
Market Cap
$67.65M
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
209 of 774
Rank in Industry
12 of 42

Largest Insider Buys in Sector

VNRX Stock Price History Chart

VNRX Stock Performance

About VolitionRx Limited

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, …

Insider Activity of VolitionRx Limited

Over the last 12 months, insiders at VolitionRx Limited have bought $151,800 and sold $33,000 worth of VolitionRx Limited stock.

On average, over the past 5 years, insiders at VolitionRx Limited have bought $441,409 and sold $246,254 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Innes Guy Archibald (director) — $115,900. Butera Salvatore Thomas (CEO - Volition Veterinary) — $16,000. Futcher Edward (director) — $7,200.

The last purchase of 150,000 shares for transaction amount of $100,500 was made by Innes Guy Archibald (director) on 2024‑08‑20.

List of Insider Buy and Sell Transactions, VolitionRx Limited

2024-08-20Purchasedirector
150,000
0.1651%
$0.67$100,500+4.86%
2024-01-02Sale10 percent owner
20,000
0.0222%
$0.90$18,000-30.05%
2023-12-18PurchaseCEO - Volition Veterinary
10,000
0.0135%
$0.83$8,300-4.71%
2023-12-15Sale10 percent owner
20,000
0.0244%
$0.75$15,000-2.75%
2023-12-15PurchaseCEO - Volition Veterinary
10,000
0.0125%
$0.77$7,700-2.75%
2023-12-13PurchaseSecretary
10,000
0.0133%
$0.60$6,000+29.11%
2023-12-08PurchasePresident and CEO
10,000
0.0131%
$0.67$6,700+12.73%
2023-11-27Purchasedirector
20,000
0.0247%
$0.77$15,400-5.06%
2023-11-27Purchasedirector
9,000
0.0115%
$0.80$7,200-5.06%
2023-11-24Purchasedirector
10,000
0.013%
$0.76$7,600-1.51%
2023-11-22Purchasedirector
20,000
0.0252%
$0.71$14,200+1.51%
2023-11-16PurchaseCEO - Volition Veterinary
10,000
0.0134%
$0.81$8,100-5.12%
2023-09-05Purchasedirector
5,000
0.0066%
$1.30$6,500-39.54%
2023-08-31Purchasedirector
9,716
0.0127%
$1.28$12,436-39.92%
2023-08-31Purchasedirector
3,706
0.0047%
$1.25$4,633-39.92%
2023-08-30PurchaseChief Scientific Officer
8,750
0.0113%
$1.27$11,113-39.36%
2023-08-29PurchaseChief Scientific Officer
11,250
0.0142%
$1.24$13,950-40.24%
2023-08-25PurchaseChief Scientific Officer
20,000
0.0258%
$1.24$24,800-37.46%
2023-08-24PurchaseChief Operating Officer
5,000
0.0064%
$1.23$6,150-35.87%
2023-08-24Purchasedirector
5,000
0.0063%
$1.22$6,100-35.87%

Insider Historical Profitability

<0.0001%
Reynolds Cameron JohnPresident and CEO
1704518
1.8394%
$0.7382+12.08%
Innes Guy Archibalddirector
406683
0.4389%
$0.73110<0.0001%
Eight Corp Ltd10 percent owner
298419
0.322%
$0.7313<0.0001%
Butera Salvatore ThomasCEO - Volition Veterinary
99350
0.1072%
$0.73130<0.0001%
Rootsaert Rodney GerardSecretary
78652
0.0849%
$0.7331+31.58%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
LAGODA INVESTMENT MANAGEMENT, LP$3.84M6.125.07M+36.06%+$1.02M2.36
The Vanguard Group$481,579.000.77636,167+1.04%+$4,941.70<0.0001
Geode Capital Management$467,464.000.74617,366+10.76%+$45,395.87<0.0001
BlackRock$434,336.000.69573,760-0.55%-$2,395.15<0.0001
Bridgeway Capital Management$131,854.000.21174,180-1.09%-$1,453.44<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.